Abstract: Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.

Abstract: The present invention relates to the use of thy1-FP (fluorescent protein) non-human transgenic animals such as mice to screen for ophthalmic agents that can be used to treat corneal dry eye syndrome and/or retinal neuropathies associated with glaucoma and/or age-related macular degeneration. Such ophthalmic agents may be selected by assessing their ability to provide protection in ocular tissue.

Abstract: A method of treating dry eye or dry eye symptom includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms. A method of stimulating the expression of PSA-NCAM in neural beds of an eye includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation may stimulate the expression of PSA-NCAM in the neural beds of the eye. A formulation includes an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).

Abstract: Topical compositions of amide derivatives of carboxylic acid non-steroidal anti-inflammatory agents are disclosed. The compositions have a reduced potential to cause mitochondrial swelling when topically administered to the eye.

Abstract: Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamer or meroxapol surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

Abstract: Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamine nonionic surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

Abstract: The topical use of 13(S)-HODE and analogs are disclosed for the treatment of dry eye disorders.

Abstract: The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.

Abstract: The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders is disclosed.

Abstract: Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.

Abstract: Ophthalmic compositions containing Lipoxin A4 and its analogs and methods of their use for treating dry eve are disclosed.

Abstract: The topical use of certain flurbiprofen amide derivatives and ketorolac amide derivatives to treat ophthalmic angiogenesis-related and inflammatory disorders of the posterior segment of the eye is disclosed.

Abstract: The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.

Abstract: The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders is disclosed.

Abstract: The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat angiogenesis-related disorders, including ophthalmic angiogenesis-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed.

Abstract: The topical use of certain flurbiprofen amide derivatives and ketorolac amide derivatives to treat ophthalmic angiogenesis-related and inflammatory disorders of the posterior segment of the eye is disclosed.

Abstract: Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.

Abstract: Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.

Abstract: 3-heteroatom substituted and two carbon homologs of 15-HETE, and their derivatives, compositions and methods of their use for treating dry eye are disclosed.

Abstract: Methods for treating post-surgical formation of cataracts or posterior capsule opacification are disclosed. The methods utilize compositions containing certain compounds having an anti-inflammatory and anti-oxidant moiety covalently linked by and amide and ester bond.